Larimar Therapeutics (LRMR) Price & Analysis

Compare

1,077 Followers

LRMR Stock Chart & Stats

$3.07

-$0.11(-2.78%)

At close: Jan 08 4:00 PM EST

$3.07

-$0.11(-2.78%)

Day’s Range― - ―

52-Week Range$1.61 - $5.37

Previous CloseN/A

Volume147.46K

Average Volume (3M)1.04M

Market Cap

$288.44M

Enterprise Value$202.65M

Total Cash (Recent Filing)$175.44M

Total Debt (Recent Filing)$4.35M

Price to Earnings (P/E)―

Beta1.84

Next Earnings

Mar 18, 2026

EPS Estimate

-0.49

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.61

Shares Outstanding85,590,390

10 Day Avg. Volume1,409,046

30 Day Avg. Volume1,040,495

Financial Highlights & Ratios

PEG Ratio-0.05

Price to Book (P/B)1.38

Price to Sales (P/S)0.00

P/FCF Ratio-3.33

Enterprise Value/Market Cap0.70

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.16K

Enterprise Value/Ebitda-1.47

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Efficacy DataOpen-label data show nomlabofusp increased skin frataxin to near-normal levels in all evaluable patients by Month 6, supporting a surrogate-endpoint strategy consistent with potential disease-modifying benefit.

Prescriber Acceptance And Market UptakeHigh prescriber willingness to accept nomlabofusp's risk–benefit profile in the setting of substantial unmet need suggests potential for meaningful adoption despite infusion-related safety concerns.

Regulatory Pathway And BLA TimelineParticipation in the FDA START program and regular agency interactions bolster the path toward a BLA submission under an accelerated-approval timeline in the second quarter of 2026.

Bears Say

Anaphylaxis Safety RiskMultiple anaphylaxis cases concentrated early in treatment represent a clear safety liability that could restrict prescribing, lead to stringent risk-mitigation measures, or limit labeling.

Regulatory Evidence StandardsRegulatory skepticism about using external natural-history comparators for rare neurologic indications raises the risk that regulators will require randomized-controlled data before granting approval.

Sector-driven Market VolatilityNegative regulatory developments for peer companies have driven notable share-price declines, indicating that continued sector skepticism could weigh on Larimar's stock and increase funding costs.

Larimar Therapeutics News

Larimar’s Pediatric Friedreich’s Ataxia Trial Termination: What Investors Should Know

Larimar Therapeutics, Inc. ($LRMR) announced an update on their ongoing clinical study. Study OverviewThis early-stage clinical trial, officially...

11d ago

LRMR

Larimar Therapeutics executes preferred stock exchange and amendment

Larimar Therapeutics ( ($LRMR) ) has provided an update. On January 21, 2026, Larimar Therapeutics entered into an...

17d ago

LRMR

Larimar advances nomlabofusp toward accelerated Friedreich’s ataxia approval

An update from Larimar Therapeutics ( ($LRMR) ) is now available. On January 12, 2026, Larimar Therapeutics posted...

26d ago

LRMR

Larimar Therapeutics Executes Strategic Stock Exchange Agreement

The latest update is out from Larimar Therapeutics ( ($LRMR) ). On December 16, 2025, Larimar Therapeutics executed...

2M ago

LRMR

Larimar Therapeutics Highlights Promising Friedreich’s Ataxia Data

Larimar Therapeutics ( ($LRMR) ) has provided an update. On November 10, 2025, Larimar Therapeutics announced an updated...

3M ago

LRMR

Larimar Therapeutics Shows Promise in Friedreich’s Ataxia Treatment

Larimar Therapeutics, Inc. ( ($LRMR) ) has released its Q3 earnings. Here is a breakdown of the information...

3M ago

LRMR

Buy Rating for Larimar Therapeutics: Optimism in Frataxin Replacement Therapy Despite Safety Concerns

Analyst Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Larimar Therapeutics and keeping the price...

3M ago

LRMR

Positive Outlook for Larimar Therapeutics Amidst Regulatory Challenges: Buy Rating Justified

William Blair analyst Myles Minter has reiterated their bullish stance on LRMR stock, giving a Buy rating today....

3M ago

LRMR

Larimar Therapeutics reports Q3 EPS (61c), consensus (42c)

“We were pleased to recently share exciting long-term data from our open label study showing consistent directional improvement...

3M ago

LRMR

Larimar Therapeutics sees cash runway into 4Q26

As of September 30, 2025, the Company had cash, cash equivalents and marketable securities totaling $175.4 million with...

3M ago

LRMR

Larimar Therapeutics Advances Phase 1 Study on Nomlabofusp for Friedreich’s Ataxia

Larimar Therapeutics, Inc. (($LRMR)) announced an update on their ongoing clinical study. Larimar Therapeutics, Inc. is conducting a...

3M ago

LRMR

Larimar Therapeutics Reports Promising Clinical Data Update

Larimar Therapeutics ( ($LRMR) ) has shared an update. On October 14, 2025, Larimar Therapeutics announced updated clinical...

4M ago

LRMR

Larimar Therapeutics price target lowered to $21 from $26 at Oppenheimer

Oppenheimer analyst Andreas Argyrides lowered the firm’s price target on Larimar Therapeutics (LRMR) to $21 from $26 to...

4M ago

LRMR

Citizens JMP healthcare analysts hold an analyst/industry conference call

Halthcare Analysts discuss the patiet community perspective on Friedreich’s Ataxia (relevant companies LRMR BIB PTCT LXEO DSGN) on...

4M ago

BIIB

DSGN

LRMR FAQ

What was Larimar Therapeutics, Inc.’s price range in the past 12 months?

Larimar Therapeutics, Inc. lowest stock price was $1.61 and its highest was $5.37 in the past 12 months.

What is Larimar Therapeutics, Inc.’s market cap?

Larimar Therapeutics, Inc.’s market cap is $288.44M.

When is Larimar Therapeutics, Inc.’s upcoming earnings report date?

Larimar Therapeutics, Inc.’s upcoming earnings report date is Mar 18, 2026 which is in 38 days.

How were Larimar Therapeutics, Inc.’s earnings last quarter?

Larimar Therapeutics, Inc. released its earnings results on Nov 05, 2025. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.404 by -$0.206.

Is Larimar Therapeutics, Inc. overvalued?

According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Larimar Therapeutics, Inc. pay dividends?

Larimar Therapeutics, Inc. does not currently pay dividends.

What is Larimar Therapeutics, Inc.’s EPS estimate?

Larimar Therapeutics, Inc.’s EPS estimate is -0.49.

How many shares outstanding does Larimar Therapeutics, Inc. have?

Larimar Therapeutics, Inc. has 85,590,390 shares outstanding.

What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?

Larimar Therapeutics, Inc. reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.404. Following the earnings report the stock price went down -15.263%.

Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?

Currently, no hedge funds are holding shares in LRMR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Larimar Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-78.24%

Trailing 12-Months

Asset Growth

-14.46%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.